Option Care Health (NASDAQ:OPCH) Price Target Raised to $41.00 at JPMorgan Chase & Co.

Option Care Health (NASDAQ:OPCH) had its target price hoisted by investment analysts at JPMorgan Chase & Co. from $40.00 to $41.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 20.55% from the company’s previous close.

A number of other equities analysts have also weighed in on OPCH. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $26.00 to $35.00 in a research report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and issued a $30.00 target price (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $26.00 to $33.00 in a research report on Monday, January 13th. UBS Group began coverage on Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Barrington Research boosted their target price on Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.00.

Option Care Health Stock Performance

Shares of Option Care Health stock opened at $34.01 on Thursday. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 2.30 and a beta of 1.33. The firm’s 50-day moving average is $29.83 and its 200 day moving average is $28.20. Option Care Health has a 1 year low of $21.39 and a 1 year high of $34.85. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32.

Insider Activity

In other news, insider Michael Bavaro sold 30,996 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares of the company’s stock, valued at $1,495,835.24. This represents a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Mackenzie Financial Corp grew its stake in shares of Option Care Health by 1.1% during the 4th quarter. Mackenzie Financial Corp now owns 49,579 shares of the company’s stock valued at $1,150,000 after acquiring an additional 556 shares during the period. Peak Retirement Planning Inc. bought a new position in shares of Option Care Health during the 4th quarter valued at approximately $1,026,000. Public Employees Retirement System of Ohio grew its stake in shares of Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock valued at $43,000 after acquiring an additional 332 shares during the period. PharVision Advisers LLC bought a new position in shares of Option Care Health during the 4th quarter valued at approximately $251,000. Finally, Voloridge Investment Management LLC bought a new position in Option Care Health in the 4th quarter worth approximately $27,428,000. 98.05% of the stock is currently owned by institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.